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patients diagnosed between January 2005-December 2014 who under-
went treatment with institutional ALL protocol (MCP-841) with or without
Imatinib. No patient underwent SCT. EFS was calculated from date of
diagnosis to date of relapse/progressionwhile OS was calculated from date
of diagnosis to date of last follow up.
Results: A total of 104 patients were diagnosed with Ph+ ALL. The median
age 11 years vs 7.9 years, Male:Female ratio of 4:1 vs 2:1 and median WBC
count 88,000 cells/mm3 vs 40,514 cells/mm3 was higher compared to
west. Similarly CNS involvement: 4 were CNS II (5%) and15 were CNS III
(20%) was higher compared to 6% inwest. Also, 86% children had NCI high-
risk disease compared to 60% inwest. Of 94 patients who started therapy at
our centre, 72 patients received Imatinib during their treatment: 29 during
induction and 43 post-induction. Fourteen did not receive Imatinib and 8
abandoned therapy before response evaluation. Median overall survival
(OS) of the entire cohort was 18 months and estimated 5-year OS and EFS
was 29% and 23% respectively. OS for patients who received Imatinib at any
time during therapy was 38%. However, none of the patients who did not
get Imatinib survived for 3 years. Five-year EFS in patients who received
Imatinib in induction was signiﬁcantly worse at 23% compared to 34% for
those who started it post-induction (p¼0.03). However, there was no
statistical difference in toxic deaths and morphologic remissions between
the groups. The 5-year overall survival of NCI low-risk group 57%
compared to 24% in NCI-high risk group.
Conclusion: Ph+ ALL is more common in India and presents with higher
age and white cell count, as well as high prevalence of CNS involvement
and NCI high-risk disease. Outcome of Ph+ALL without Imatinib and stem
cell transplantation is dismal. Combined therapy including aggressive
chemotherapy and Imatinib improves outcome but outcome of NCI-High
risk disease is suboptimal.
Keywords: Philadelphia-Positive Acute Lymphoblastic Leukemia, Imatinib,
Children
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EXPRESSION OF B LYMPHOCYTE ANTIGEN IN PEDIATRIC B-CELL
PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: AIIMS EXPERIENCE
Nivedita Pathak 1, Rachna Seth 1, Akhilesh Mishra 2. 1Department of
Pediatrics, Dr BRAIRCH, All India Institute of Medical Sciences, New Delhi,
India; 2Department of Radiation Oncology, Dr BRAIRCH, All India Institute
of Medical Sciences, New Delhi, India
E-mail address: nivisaiims@gmail.com (N. Pathak).
Background: Majority of mature B-ALL blasts express B lymphocyte an-
tigen (CD20) on their surface however, only 30- 50% of B-cell precursor ALL
blasts express CD20. The incongruous expression of CD20 in BCP-ALL pa-
tients and its prognostic relevance has been reported in adult and pediatric
cases but with discrepant results. In view of this we aimed to determine
the prognostic impact of CD20 expression in pediatric BCP-ALL patients
treated at our department.
Aim of the study: To investigate and correlate the expression proﬁle of
CD20 in precursor B-cell ALL patients with treatment outcome.
Methodology: Mononuclear cells were isolated using ﬁcoll-histopaque
layering technique from bone marrow (BM)/peripheral blood (PB) sam-
ples. Immunophenotyping of blast cells at diagnosis was done by multi-
parametric ﬂow cytometry. Expression of antigens on leukemic cells was
determined by using a 6-dimensional space formed by 2 light scatter pa-
rameters (forward scatter [FSC] and side scatter [SSC]) and 4 ﬂuorescence-
associated characteristics. The existence of blast cell population was
established on the basis of abnormal antigen expression proﬁles of the
blasts as compared to the control.
Results: A total of 65 pediatric patients (median age 9 yrs, range 1-17 yrs;
M: F 4:1; median TLC-17.4x109/l, range 1.1-715x109/l) were studied. CD20
positivity was deﬁned as more than 20% of leukemia blasts expressing
surface CD20. Expression of CD20 was present in 37/65 (57%) patients with
BCP ALL. A worse outcome has been observed in our patients expressing
CD20 than thosewithout the expression. Disease free survival at 20months
in CD20-positive and CD20-negative groups (33% [95% CI, 10-54] versus
89% [95% CI, 54-96], P¼0.002) was statistically signiﬁcant. Overall survival
at 18 months (46% [95% CI, 26-61] versus 65% [95% CI, 40-78], P¼0.01) was
also poorer in CD20-positive group than CD20-negative group.Conclusion: Expression of CD20 on leukemic blasts found to be higher in
our pediatric ALL patients and is associated with poorer outcome as
compared to mostly reported in various studies. This should be explored
further in Indian scenario with regard to prognosis.
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PEDIATRIC PLASMABLASTIC LYMPHOMA e TEN YEARS EXPERIENCE IN
A TERTIARY CARE CENTRE IN INDIA
Nirmalya Pradhan, Saroj Panda, Gaurav Narula, Brijesh Arora, Shripad
Banavali. Tata Memorial Hospital, Mumbai, India
Introduction: Plasmablastic lymphoma is a rare form of non Hodgkin
lymphoma. Little data exists on its epidemiology and outcome in children.
We aimed to study the clinical, epidemiological proﬁle and outcome of
plasmablastic lymphoma in our centre.
Methods and materials: This is a retrospective analysis of 10 years data
from January-2006 to December-2015 at Tata Memorial Centre, Mumbai.
Analysis included all children who presented to our hospital during this
period and diagnosed to have plasmablastic lymphoma by histopathology
and immunohistochemistry. Patients received various multiagent
chemotherapeutic regimens. The outcome of these patients was analyzed.
Results: Thirteen cases of pediatric plasmablastic lymphoma were diag-
nosed and treated in our center during the study period. Elevenwere male
and 2 female. Median age at diagnosis was 12 years (Range1-15 years). HIV
infection was detected in all except 3 children. Four patients had B
symptoms at presentation. Various sites of involvement at diagnosis were
lymph nodes (9 patients), paranasal sinuses (7 patients), bone (4 patients),
pleura (1 patient), orbit (1 patient) and soft tissue (1 patient). Bone
marrow and CSF were involved in 5 and 2 patients respectively, while 2
patients had involvement of both. Patients were given various multi agent
chemotherapeutic regimens like MCP-842, CVEP (Cyclophosphamide,
Vincrstine, Etoposide, Prednisolone), EPOCH (Etoposide, Prednisolone,
Vincristine, Cyclophosphamide, Adriamycin) and oral metronomic
chemotherapy (6-Thioguanine, Etoposide). All patients with HIV infection
also received antiretroviral therapy. At last follow up, 4 patients were
disease free, 6 patients died of disease progression, 1 patient died of cause
unrelated to disease and 2 patients lost to follow up (one patient HIV
positive and one HIV negative).
Conclusion: Plasmablastic lymphoma is an aggressive non Hodgkin lym-
phoma in children. Majority of cases are HIV positive and present with
disseminated disease. The most common sites of involvement include
lymph nodes and paranasal sinuses. Despite intensive chemotherapy
outcome is poor.
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FEASIBILITY OF A MITOXANTRONE-BASED INDUCTION PROTOCOL IN
CHILDHOOD ACUTE MYELOID LEUKEMIA: FOLLOW UP EXPERIENCE
OF 2 YEAR COHORT FROM TATA MEDICAL CENTER, KOLKATA
Dipshikha Maiti, Shekhar Krishnan, Anirban Das, Mayur Parihar, Neeraj
Arora, Sanjay Bhattacharya, Arpita Bhattacharyya, Vaskar Saha. Tata
Medical Center, Kolkatta, India
Background: Acute myeloid leukemia (AML) is a difﬁcult disease to treat
in resource limited settings. Data from India is limited to identify trends/
shortcomings, and plan remedial strategies.
Objective: To analyze the clinical proﬁle and outcome in children with
AML treated with mitoxantrone-based induction protocol.
Method:
Study type: Retrospective observational study.
Study Setting: Undertaken between January 2014 and December 2015 in
Tata Medical Center, Kolkata.
Inclusion criteria: <18-years, presenting with a diagnosis of de novo AML.
Exclusion criteria: Acute promyelocytic leukemia, Down syndrome and
secondary AML.
Classiﬁcation & Stratiﬁcation: Genetic classiﬁcation by a combination of
karyotyping with G banding technique and FISH analysis for t(8;21), inv 16,
t(15;17), MLL gene rearrangements in all children.
Stratiﬁed based on the WHO classiﬁcation to standard, intermediate and
high-risk groups.
Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S10Intervention: Treated with anthracycline-based induction (mitoxantrone
12 mg/m2/day x 3 doses +cyatarabine 100 mg/m2/dose 12 hrly d1 to d10,
daunorubicin 50 mg/m2/day x 3 doses +cyatarabine), followed by
consolidation with 2 cycles of high-dose (3g/m2) cyatarabine. Stem cell
transplantation was not performed.
Analysis: Data extracted from the medical records. Patient identity was
masked. Kaplan-Meier method was used for survival analysis.
Outcome:
i. Proportion of cases achieving remission
ii. Event free survival (EFS)
Result: Of the 39 children presenting to the centre, 27 (69.2%) received
treatment. Twenty-ﬁve (92.5%) receivedmitoxantrone in induction.Median
age was 11.1 years (range:1.08-17.1) with a slight female preponderance
(F:M¼1.2:1).Median follow-upwas16months (range:5-23).Most common
reason for treatment-refusal was ﬁnancial constraint. Themajor presenting
complaints included fever (100%) patients and bleeding manifestations
(66.7%). Rare presentations include paraparesis (epidural mass on MRI
spine), bilateral proptosis (one case each). No patient had CNS disease.
WBC count was 13,600 (range: 600-3,56,000). Hyperleucocytosis was
documented in 3 patients (11%).
The most frequent genetic abnormality was t (8;21). 22.2% had a normal
karyotype. Patients in standard (SR), intermediate (IR), and high-risk (HR)
groups were 10 (37.1%), 11 (40.7%) and 6 (22.2%), respectively
Complete remission was achieved in 76.9% after induction-1, and 80.8%
after induction-2. Two (7.4%) children had refractory disease. Both had
received daunorubicin-based induction. Other events included 6 non
relapse deaths (22.5%). Of these 5 were toxicity-related deaths (18.5%, 2
deaths in CR), and 1 death due to intracranial bleed (3.5%). 5 patients
relapsed (18.5%). Event free survival (EFS) at 2.5 years was 52 %. EFS of SR,
IR, HRgroup was 80%, 45.5% and 16.7% respectively.
Commonest cause of non-relapse mortality was multidrug-resistant sepsis
(5/9 deaths), with Klebsiella pneumoniae (n¼4/5, 80%) being the com-
monest isolate.
Conclusion: Complete remission and relapse rates were comparable to
that reported from developed countries; however, these were partly offset
by higher toxicity-related deaths. Favourable outcome was noted in the
standard-risk group.
Feasibility of a mitoxantrone-based induction protocol was demonstrated,
and plausibly contributed to the favourable outcome. Support for equitable
access to healthcare, conformity to a standard protocol, and optimization
of supportive care, would help us further improve outcomes.
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DETECTION OF THE THREE FUSION ONCOGENES OF CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKEMIA e SINGLE CENTRE EXPERIENCE
G. Krishna Sameera, Julius Scott, Tina Koshy, M.S. Latha. Sri Ramchandra
Univeristy, India
Background/Objectives: Chromosomal abnormalities, such as
t(9;22)(q34;q11) (ABL/BCR), t(12;21)(p13;q22) (TEL/AML1), and t(11q23)
(MLL) are independent prognostic indicators in childhood acute lympho-
blastic leukemia resulting in risk adapted therapy. Accurate and rapid
detection of these abnormalities is mandatory, which is achieved by kar-
yotyping, ﬂuorescence in situ hybridization (FISH), and real time quanti-
tative reverse transcriptase polymerase chain reaction (RQ-PCR). Risk
stratiﬁcation helps in improving the survival rates and the lack of adequate
and appropriate diagnostic facilities in developing countries are identiﬁed
as one of the causes of low survival rates.
Design/Methods: The aim of thr study was to identify the incidence of
common fusion oncogenes of childhood acute lymphoblastic leukemia and
to assess the sensitivity and speciﬁcity of the tests used to identify the
fusion oncogenes.The study was conducted on 35 patients being treated
for ALL in our institution. Diagnostic tests of karyotyping, FISH and RT-PCR
were performed according accepted protocols and standards.Study was
approved by institution ethics committee and funded by GATE project of
SRU.
Results: The frequency of t(9;22)(q34;q11) (BCR/ABL), t(12;21)(p13;q22)
(TEL/AML1), and t(11q23) (MLL) was found to be 3%,6% and 2% respecti-
vely.The adopted diagnostic techniques had a high-individual diagnostic
accuracy in detecting the above-mentioned chromosomal translocations.However, the sensitivity of karyotyping for detecting the TEL-AML1 fusion
gene and MLL-rearrangements was low.
Conclusion: Despite the high-diagnostic accuracy, all diagnostic tech-
niques should be used complementary, because any detection of a signif-
icant chromosomal aberration irrespective of diagnostic mode has to be
considered in therapy. However, a larger study population would establish
the diagnostic accuracy of the three techniques as well as the frequency of
these genetic alterations in children with ALL.
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SOCIO-ECONOMIC STATUS AND SURVIVAL IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA
Sidharth Totadri, Amita Trehan, Appinderjit Kaur, Deepak Bansal, Richa
Jain. PGIMER, Chandigarh, India
Background: Survival in malignancies in low income countries is poor in
comparison to high income countries, reasons ranging from lack of
adequate care, malnutrition, higher proportion with adverse prognostic
factors, abandonment and high incidence of toxic deaths.
Aim: To analyze the effect, if any, of socioeconomic (SE) status and parental
educational status on outcome in childhood acute lymphoblastic leukemia
(ALL).
Methods: Children who were diagnosed and treated for ALL from January
2010 to December 2012 were included in this retrospective analysis. Pa-
tients were treated as per modiﬁed UKALL-2003 protocol. Details of
parental education, occupation and income were noted from the database
maintained by the social worker. Modiﬁed Kuppuswamy scale (KS) was
used to classify patients into upper, middle and lower SE strata. Educa-
tional status of parents was classiﬁed as per the criteria provided in KS.
Induction failure, death and relapse were included as events for Kaplan-
Meier survival analysis.
Results: The study included 308 patients with median age of 5 years
(range: 1-13). Male to female ratio was 2.5:1. Patients belonging to upper,
middle and lower SE strata numbered 85 (28%), 68 (22%) and 155 (50%).
Fathers and mothers were graduates in 75 (24%) and 62 (20%) children.
Fathers and mothers had at least high school education in 193 (63%) and
175 (57%) patients. Fathers of girls who received treatment for ALL were
more likely to have passed high school as compared to boys [72% vs. 59%,
p¼0.026]. Maternal educational status as well as SE status did not differ
with gender. Sixteen patients (5.2%) abandoned treatment. None of the
patients whose mothers were graduates abandoned treatment (p¼0.025).
Treatment abandonment did not differ signiﬁcantly between the 3 SE
strata (p¼0.340). Fifty-eight (19%) patients died due to neutropenic sepsis
during treatment. Twenty-seven (8.8%) patients died during induction.
Induction mortality did not differ with SE status (p¼0.334), paternal
(p¼0.300) or maternal educational status (p¼0.100). Neutropenic sepsis
related deaths occurred in 19 patients during maintenance therapy. Death
during maintenance therapy was signiﬁcantly lower in families where the
mother was educated up to high school in comparison to lesser educated
mothers (p¼0.03). Event-free-survival (EFS) was 58.1±3.1% and overall-
survival (OS) was 74.8±2.7% for the entire cohort. In patients who sur-
vived induction therapy, the EFS of upper SE stratum was signiﬁcantly
better: 78.7±4.9% vs. 59±7.2 and 58.1±4.6% in middle and lower strata
(p¼0.026, Fig. 1). OS, though statistically not signiﬁcant, was higher in the
higher SE group; being 91.2±3.5%, 78.3±5.6% and 78.8±3.9% (p¼0.085)
respectively in the 3 strata.
Conclusions: Higher socioeconomic status contributes to superior EFS
in children with ALL who achieve remission. It is noteworthy that girls
receiving treatment ALL are more likely to have educated fathers.
Additionally, maternal educational is signiﬁcantly associated with
reduction in treatment abandonment and death during maintenance
therapy.
